Explaining discrepant mortality results between primary percutaneous transluminal coronary angioplasty and thrombolysis for acute myocardial infarction

American Journal of Cardiology

Volumn 78, Issue 8, 1996, Pages 934-939

  Anderson, Jeffrey L ^a   Karagounis, Labros A ^a   Muhlestein, Joseph B ^a  

^a LDS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EDITORIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REGISTER; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ALGORITHMS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; HOSPITAL MORTALITY; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; REGISTRIES; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030587927     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm - paradoxic or predictable? Circulation 1993;88:296-306.
2. Raitt MH, Maynard C, Wagner GS, Cerqueira MD, Selvester RH, Weaver WD. Relation between symptom duration before thrombolytic therapy and final myocardial infarct size. Circulation 1996;93:48-53.
3. Bassand J-P, Machecourt J, Cassagnes J, Anguenot T, Lusson R, Borel E, Peycelon P, Wolf E, Ducellier D, for the APSIM Study Investigators. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function. J Am Coll Cardiol 1989;13:988-997.
4. Fibrinolytic Therapy Trialists' Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more thatn 1000 patients. Lancet 1994;343:311-322.
5. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW, for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
6. Zijlstra F, de Boer MJ, Hoorntje JE, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
7. Gibbons R, Holmes DR, Reeder GS, Bailey KR, Hopfenspringer M, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-691.
8. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? Circulation 1994;91:476-485.
9. Weaver WD, Litwin PE, Martin JS. Use of direct angioplasty for treatment of patients with acute myocardial infarction in hospitals with and without onsite cardiac surgery. TheMITI Project Investigators. Circulation 1993;88:2067-2075.
10. Rogers WJ, Dean LS, Moore PB, Wool KJ, Burgard SL, Bradley EL. Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Alabama Registry of Myocardial Ischemia Investigators. Am J Cardiol 1994;74:111-118.
11. Cannon CP, Henry TD, Schweiger MJ, Haugland JM, McKendall GR, Shah PK, Gleason R, McCabe CH, Antman EM, Braunwald E, and the TIMI 9 Registry Investigators and Coordinators. Current management of ST elevation myocardial infarction and outcome of thrombolytic ineligible patients: results of the multicenter TIMI 9 registry. J Am Coll Cardiol 1995;25:231A (755-752).
12. Every N, Weaver WD, Parsons L, Martin JS, for the MITI Project Investigators. Direct PTCA vs thrombolysis: immediate and one year outcome and procedure utilization for the two treatment strategies. Circulation 1995;92:1-138 (654).
13. Tiefenbrunn AJ, Chandra NC, French WJ, Rogers WJ, for the Second National Registry of Myocardial Infarction (NRMI 2) Investigators. Experience with primary PTCA compared to alteplase in patients with acute myocardial infarction (abstr). Circulation 1995;92(suppl I):1-138.
14. Rogers WJ. National Registry of Myocardial Infarction 2. Quarterly Data Report. December, 1995. Clin Trial Research, Inc, Lexington, KY.
15. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death: T. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-794.
16. The GUSTO Investigators An international randomized trial comparing four thrombnlytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682; 331:277,687.
17. The GUSTO Investigators An international randomized trial comparing four thrombnlytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682; 331:277,687.
18. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase. or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329;1615-1622.
19. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf R, Ross AM, for the GUSTO-1 Investigators. Link between the angiographie substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.
20. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thrombosis and Thrombolysis 1994;1:27-34.
21. Cannon CP, Lambrew CT, Tiefenbrunu AJ, French WJ, Gore JM, Weaver D, Rogers WJ, for the NRMI-2 Investigators. Influence of door-to-balloon time on mortality in primary angioplasty results in 3,648 patients in the Second National Registry of Myocardial Infarction (NRMI-2) (abstr). J Am Coll Cardiol 1996,27 (suppl A):61A.
22. Oranger CB, Califf RM. Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992;44;293-325.
23. Chesebro JH, Knatterud G, Roberts R, Borer J. Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mucller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO. Zaret BL, Braunwald E, Thrombolysis in myocardial infarction (TIMI) trial, phase I; a comparison between intravenous plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-154.
24. Simoons ML, Betriu A, Col J, von Essen R, Lubsen J, Michel PL, Rutsch W, Schmidt W, Thery C, Vahanian A, Willcms GM, Arnold AER, DeBono DP, Dougherty FC, Lambertz H, Meier B, Raynaud P, Sanz GA, Serruys PW, Uebis R, Van de Werf F, Wood D. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate pereutaneous coronary angioplasty. Lancet 1988;1:197-203.
25. Carney RJ, Murphy GA, Brandt TR, Daley PI, Pickering E, White HI, McDonough TH, Vermilya SK, Teichman SL, for the RAAMI Study Investigators. Randomized angiographie trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction, J Am Coll Cardiol 1992,20:17-23.
26. Anderson JL, Karagounis LA, Califf RA. Metaanalysis of 5 reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996:78:1-8.
27. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequéira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri ST, Davis V, Gibson CM, Poole WK, Braunwald E, for the TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction; results of the Thrombolysis In Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602-1610.
28. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, Boersma E, Franzosi MG, Califf R, Schröder R, Braunwald E. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993;342;1523-1528,
29. Ohman EM. Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, Geofge B, Stack R, and the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.
30. Jollis JG, Peterson ED, DeLong ER, Mark DB, Collins SR, Muhlbaier LH, Pryor DB. The relation between the volume of coronary angioplasty procedures at hospitals treating medicare beneficiaries and short-term mortality N Engl J Med 1994;331:1625-1629.
31. Anderson I, Karagounis LA Does intravenous heparin or time-to-treatment/ reperfusion explain differences between GUSTO and ISIS-3 results? Am J Cardiol 1994;74:1057-1060.
32. Cairns JA, Fuster V, Gore J, Kennedy JW. Coronary thrombolysis. Chest 1995;108 (suppl) :401S-423S.